Pharmafile Logo
Pharmafocus logo
Advanced Search

Entyvio

Showing 10 posts of 10 posts found.

takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020
Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …

News
entrance_takeda_i020_v1

Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease

February 17, 2020
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …

News
takeda_deerfield_hq

Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease

July 23, 2019
Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma

Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …

News
takeda_global_hq

Takeda scores Japanese Entyvio approval in Crohn’s disease

May 22, 2019
Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma

Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …

News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019
Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …

News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio secures Japanese approval in ulcerative colitis

July 2, 2018
Sales and Marketing Entyvio, Japan, Takeda, pharma, ulcerative colitis

Takeda Pharmaceutical has announced that its monoclonal antibody, Entyvio (vedolizumab), has been approved for the treatment of patients with moderately …

News
takeda_research_centre

Takeda presents long-term Entyvio data in CD and UC

March 21, 2016
Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis

Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …

News
Entyvio

NICE u-turns on Entyvio for Crohn’s disease

July 10, 2015
Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding

NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …

News
Entyvio image

NICE rejects Takeda Crohn’s disease drug

December 23, 2014
Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab

Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …

News

Latest content

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023